Use of Naltrexone to Treat Opioid Addiction in a Country in Which Methadone and Buprenorphine Are Not Available
- 595 Downloads
Opioid dependence is one of the most severe drug dependencies. Naltrexone is a medication that completely blocks the subjective and other effects of opioids and, when administered to detoxified opioid addicts and taken as directed, prevents relapse and helps maintain abstinence. The major problem with naltrexone is poor compliance, particularly in countries in which there is a treatment alternative based on substitution of illicit opioids such as heroin with orally administered opioid agonists (methadone) or partial agonist/antagonists (buprenorphine). In Russia, substitution therapy is forbidden by law, and naltrexone is the only available pharmacotherapy for heroin dependence. Due to the lack of alternatives to naltrexone and stronger family control of compliance (adherence), naltrexone is more effective for relapse prevention and abstinence stabilization in Russia than in Western countries. Long-acting, sustained-release formulations (injectable and implantable) seem particularly effective compared with oral formulations. This article summarizes the results of studies conducted in Russia during the past 10 years that demonstrate these points.
KeywordsNaltrexone Opiate dependence Pharmacotherapy
The studies of oral naltrexone with or without fluoxetine were supported by National Institute on Drug Abuse grants P60-DA05186l (to Dr. Charles P. O’Brien), U10-DA13043, and K05-DA 17009 (to Dr. Woody) and the Department of Veterans Affairs. The study of implant naltrexone was supported by National Institute on Drug Abuse grant DA017317.
DuPont Pharmaceutical provided naltrexone, and Gideon Richter provided fluoxetine for the studies of oral naltrexone with or without fluoxetine. Fidelity Capital (Russia) provided Prodetoxon at reduced cost. Alkermes (USA) supported the study of injectable naltrexone (Vivitrol) in Russia.
Dr. Krupitsky serves a consultant for Alkermes. No other potential conflicts of interest relevant to this article were reported.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 7.Rounsaville B: Can psychotherapy rescue naltrexone treatment of opioid addiction? In Potentiating the Efficacy of Medications: Integrating Psychosocial Therapies With Pharmacotherapies in the Treatment of Drug Dependence. Edited by Onken L, Blaine J. Rockville, MD: National Institute on Drug Abuse; 1995:37–52. [NIDA Research Monograph series no. 105, NIH publication no. 95-3899.]Google Scholar
- 10.•• World Health Organization: Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. Geneva, Switzerland: World Health Organization; 2009. The guidelines review the use of medications such as methadone, buprenorphine, naltrexone, and others in combination with psychosocial support in the treatment of individuals dependent on heroin or other opioids. Based on the systematic review of the literature, the guidelines contain specific recommendations on the range of issues faced in organizing treatment systems, managing treatment programs, and treating those who are dependent on opioids.Google Scholar
- 17.• Hulse GK, Morris N, Arnold-Reed D, et al.: Improving clinical outcomes in treating heroin dependence. Arch Gen Psychiatry 2009, 66:1108–1115. This first double-blind, placebo-controlled, randomized clinical trial showed the effectiveness of the single-dose Australian naltrexone implant in comparison with oral naltrexone. CrossRefPubMedGoogle Scholar
- 18.• Kunøe N, Lobmaier P, Vederhus JK, et al.: Naltrexone implants after in-patient treatment for opioid dependence: randomized controlled trial. Br J Psychiatry 2009, 194:541–546. This Norwegian study compared the Australian implantable naltrexone with usual-treatment aftercare.CrossRefPubMedGoogle Scholar
- 19.•• Krupitsky EM, Blokhina EA: Long acting sustained release formulations of naltrexone for heroin dependence: a review. Curr Opin Psychiatry 2010, 23:210–214. This is a review of the most recent data on the variety of long-acting, sustained-release formulations of naltrexone (implantable and injectable) and their use for opiate dependence, including their efficacy and safety.CrossRefGoogle Scholar
- 23.Alkermes announces positive results from phase 3 clinical study of naltrexone for extended-release injectable suspension for the treatment of opioid dependence. Cambridge, MA: Alkermes; November 16, 2009. Available at http://investor.alkermes.com/phoenix.zhtml?c = 92211&p = irol-newsArticle&ID = 1355632&highlight.
- 24.• Fishman M: Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone. Addiction 2008, 103:1399–1401. This clinical case demonstrated that it is possible to overcome opioid blockade with Vivitrol and precipitate withdrawal in some circumstances. CrossRefPubMedGoogle Scholar